Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up platform study of pulmonary hypertension parent-study treatments
2023-506791-27-00Phase 3Authorised
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label trial of macitentan, selexipag, tadalafil and ACT-1014-6470 in pulmonary arterial hypertension (PAH) (3 cohorts), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Treatment-emergent adverse events, Treatment-emergent adverse events leading to discontinuation and 2 more. Planned start Apr 2022; status: authorised.
02
Drugs
macitentanselexipagtadalafilACT-1014-6470
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-506791-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506791-27-00.